79 related articles for article (PubMed ID: 15687986)
1. [Criteria of choice for first-line chemotherapy for Stage IV disease].
Fournel P
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S8-4S12. PubMed ID: 15687986
[No Abstract] [Full Text] [Related]
2. [Treatment of non-small-cell lung carcinoma: PS2 patients' particularities].
Deppermann KM
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S31-4S34. PubMed ID: 15687991
[No Abstract] [Full Text] [Related]
3. [Management of non-small-cell lung cancer (NSCLC) in elderly patients].
Westeel V
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S35-4S38. PubMed ID: 15687992
[No Abstract] [Full Text] [Related]
4. [Multimodal therapy of small cell and non-small cell lung carcinoma].
Serke M; Kollmeier J
Dtsch Med Wochenschr; 2007 Jun; 132(22):1221-4. PubMed ID: 17520508
[TBL] [Abstract][Full Text] [Related]
5. The role of targeted agents in adjuvant therapy for non-small cell lung cancer.
Kelly K
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5027s-5029s. PubMed ID: 16000608
[TBL] [Abstract][Full Text] [Related]
6. [Second-line chemotherapy in non-small-cell lung cancer].
Schütte W
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 3):4S13-4S16. PubMed ID: 15687987
[No Abstract] [Full Text] [Related]
7. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
Besse B; Le Chevalier T
J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
[No Abstract] [Full Text] [Related]
8. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
Zhou DH; Lin LZ; Zhou YQ; Luo RC; Liu KF; Jia YJ; Chen JY; Niu XW; Su BR; Lu J; Wang ST
Ai Zheng; 2005 Oct; 24(10):1252-6. PubMed ID: 16219143
[TBL] [Abstract][Full Text] [Related]
9. Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer.
Johnson DH; Rusch VW; Turrisi AT
J Natl Cancer Inst; 2007 Mar; 99(6):415-8. PubMed ID: 17374824
[No Abstract] [Full Text] [Related]
10. [Chemotherapy in cancer of the lung].
Gütz S
MMW Fortschr Med; 2006 Jun; 148(22):33-4. PubMed ID: 16821578
[TBL] [Abstract][Full Text] [Related]
11. Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?
Azzoli CG
Nat Clin Pract Oncol; 2005 Nov; 2(11):552-3. PubMed ID: 16270095
[No Abstract] [Full Text] [Related]
12. Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials.
Kuo SH; Yang CH; Yu CJ; Hsu C; Cheng AL; Yang PC
Lung Cancer; 2005 May; 48(2):275-80. PubMed ID: 15829329
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
14. The future of adjuvant chemotherapy for resected non-small cell lung cancer.
Vansteenkiste JF; Schildermans RH
Expert Rev Anticancer Ther; 2005 Feb; 5(1):165-75. PubMed ID: 15757448
[TBL] [Abstract][Full Text] [Related]
15. [Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].
Greillier L; Barlesi F
Rev Mal Respir; 2012 Jan; 29(1):4-6. PubMed ID: 22240212
[No Abstract] [Full Text] [Related]
16. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of non-small cell lung cancer: advanced (metastatic) disease. Guidelines of clinical practice made by the European Lung Cancer Working Party].
European Lung Cancer Working Party
Rev Med Brux; 2007; 28(6):495-511. PubMed ID: 18265809
[TBL] [Abstract][Full Text] [Related]
18. Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC).
Reck M
Anticancer Res; 2005; 25(3A):1501-6. PubMed ID: 16033051
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
20. [Non-small cell lung cancer (NSCLC): the evolution of neo-adjuvant chemotherapy in the last 15 years].
Santo A; Genestreti G; Fiorio E; Terzi A; Lonardoni A; Calabrò F; Campaldini B; Colaluca P; Molino A; Cetto GL
Recenti Prog Med; 2006 Apr; 97(4):211-8. PubMed ID: 16729492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
